TrialDiabetes, obesity & metabolism2022

The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.

Jonathan M Wilson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.